287 related articles for article (PubMed ID: 36902193)
1. Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
Ma L; Chen H; Yang W; Ji Z
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902193
[TBL] [Abstract][Full Text] [Related]
2. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
3. Integrated Analysis Revealed an Inflammatory Cancer-Associated Fibroblast-Based Subtypes with Promising Implications in Predicting the Prognosis and Immunotherapeutic Response of Bladder Cancer Patients.
Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555612
[TBL] [Abstract][Full Text] [Related]
4. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.
Zhang Z; Wang ZX; Chen YX; Wu HX; Yin L; Zhao Q; Luo HY; Zeng ZL; Qiu MZ; Xu RH
Genome Med; 2022 Apr; 14(1):45. PubMed ID: 35488273
[TBL] [Abstract][Full Text] [Related]
6. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.
Chen D; Liu J; Zang L; Xiao T; Zhang X; Li Z; Zhu H; Gao W; Yu X
Int J Biol Sci; 2022; 18(1):360-373. PubMed ID: 34975338
[TBL] [Abstract][Full Text] [Related]
7. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of tumor-infiltrating lymphocyte-related prognosis signature for predicting prognosis and immunotherapeutic response in bladder cancer.
Li C; Xie W
BMC Bioinformatics; 2023 Mar; 24(1):118. PubMed ID: 36973645
[TBL] [Abstract][Full Text] [Related]
9. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
[TBL] [Abstract][Full Text] [Related]
10. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel stemness-related signature with appealing implications in discriminating the prognosis and therapy responses for prostate cancer.
Zhang T; Li J; Dai J; Yuan F; Yuan G; Chen H; Zhu D; Mao X; Qin L; Liu N; Yang M
Cancer Genet; 2023 Aug; 276-277():48-59. PubMed ID: 37487324
[TBL] [Abstract][Full Text] [Related]
12. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
Wang Y; Chen L; Yu M; Fang Y; Qian K; Wang G; Ju L; Xiao Y; Wang X
Cancer Med; 2020 Oct; 9(20):7729-7741. PubMed ID: 32841548
[TBL] [Abstract][Full Text] [Related]
13. Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.
Chen H; Yang W; Ji Z
Front Immunol; 2023; 14():1171420. PubMed ID: 37063886
[TBL] [Abstract][Full Text] [Related]
14. A novel CD8
Lin F; Ke ZB; Xue YT; Chen JY; Cai H; Lin YZ; Li XD; Wei Y; Xue XY; Xu N
Inflamm Res; 2023 Aug; 72(8):1665-1687. PubMed ID: 37578544
[TBL] [Abstract][Full Text] [Related]
15. Machine learning identifies the role of SMAD6 in the prognosis and drug susceptibility in bladder cancer.
Chen Z; Ou Y; Ye F; Li W; Jiang H; Liu S
J Cancer Res Clin Oncol; 2024 May; 150(5):264. PubMed ID: 38767747
[TBL] [Abstract][Full Text] [Related]
16. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
Front Immunol; 2022; 13():964393. PubMed ID: 36211344
[TBL] [Abstract][Full Text] [Related]
17. Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer.
Xie T; Peng S; Liu S; Zheng M; Diao W; Ding M; Fu Y; Guo H; Zhao W; Zhuang J
Mol Cancer; 2024 Feb; 23(1):30. PubMed ID: 38341586
[TBL] [Abstract][Full Text] [Related]
18. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
[TBL] [Abstract][Full Text] [Related]
19. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
20. Dissecting Immunosuppressive Cell Communication Patterns Reveals JunB Proto-Oncogene (JUNB) Shaping a Non-Inflamed Tumor Microenvironment.
Chen H; Chen G
Front Genet; 2022; 13():883583. PubMed ID: 35812726
[No Abstract] [Full Text] [Related]
[Next] [New Search]